BG
CASC

BlackRock Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History

BlackRock Group’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-7,650
Closed -$172K – 3115
2015
Q2 		$172K Hold
7,650
– – ﹤0.01% 2623
2015
Q1 		$75K Buy
+7,650
New +$75K ﹤0.01% 2710
2014
Q2 		– Sell
-21,656
Closed -$389K – 2907
2014
Q1 		$389K Buy
+21,656
New +$356K ﹤0.01% 2313

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

BlackRock Group's CASC Position: Q3 2015 in Review

BlackRock Group sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2015, closing a stake of 7,650 shares — an estimated $172K sold.

BlackRock Group first reported a position in CASC in Q1 2014 and held it in 3 quarters. The position peaked at $389K in Q1 2014. 93 funds tracked by Wall St. Rank hold CASC as of Q3 2015.

  • BlackRock Group reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • BlackRock Group sold 7,650 Cascadian Therapeutics, Inc. shares in Q3 2015, an estimated $172K.
  • BlackRock Group first reported a position in Cascadian Therapeutics, Inc. in Q1 2014 and held it in 3 quarters.
  • BlackRock Group's Cascadian Therapeutics, Inc. position peaked at $389K in Q1 2014.
  • 93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2015.

Based on BlackRock Group's 13F filing for Q3 2015, filed 13 Nov 2015.